{"disease":{"id":"schizophrenia-agitation","name":"schizophrenia agitation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07116694","title":"Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":false},{"nct_id":"NCT06093451","title":"Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Temple University","has_results":false},{"nct_id":"NCT06041646","title":"Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"BioXcel Therapeutics Inc","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}